# A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

> **NCT07038200** · PHASE3 · RECRUITING · sponsor: **Avidity Biosciences, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Facioscapulohumeral Muscular Dystrophy
- FSHD
- FSHD - Facioscapulohumeral Muscular Dystrophy
- FSHD1
- FSHD2
- Fascioscapulohumeral Muscular Dystrophy
- Fascioscapulohumeral Muscular Dystrophy Type 1
- Fascioscapulohumeral Muscular Dystrophy Type 2
- Facioscapulohumeral Muscular Dystrophy 1
- Facioscapulohumeral Dystrophy
- Facio-Scapulo-Humeral Dystrophy
- Facioscapulohumeral Muscular Dystrophy 2
- Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)
- FSH Muscular Dystrophy
- Landouzy Dejerine Dystrophy
- Landouzy-Dejerine Muscular Dystrophy
- Landouzy-Dejerine Syndrome

## Interventions

- **DRUG:** AOC-1020
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07038200
- **Lead sponsor:** Avidity Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-10
- **Primary completion:** 2028-05
- **Final completion:** 2028-07
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07038200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07038200, "A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07038200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*